石四药集团(02005.HK)两产品获药品生产注册批件

阿斯达克财经
Apr 23, 2025

石四药集团(02005.HK) 公布,集团已取得中国国家药品监督管理局有关达格列净二甲双胍缓释片(I)及精氨酸布洛芬颗粒(0.4g 及0.2g)的药品生产注册批件,均属于化学药品第4类,视同通过一致性评价。同时,集团的阿昔莫司及二羟丙茶碱已获国家药监局批准登记成为在上市制剂使用的原料药。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-22 16:25。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10